These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30187550)

  • 1. Selectively targeting the gut in inflammatory bowel disease: Session four summary.
    Begun J
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():25. PubMed ID: 30187550
    [No Abstract]   [Full Text] [Related]  

  • 2. Selectively targeting the gut in inflammatory bowel disease: Targeting integrins.
    Parkes M
    J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():26. PubMed ID: 30187545
    [No Abstract]   [Full Text] [Related]  

  • 3. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gut microbes, immunity, and spondyloarthritis.
    Stoll ML
    Clin Immunol; 2015 Aug; 159(2):134-42. PubMed ID: 25967460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Homing Molecule Regulation of the Pathogenesis and Treatment of Inflammatory Bowel Diseases.
    Evans-Marin HL; Cong Y
    Inflamm Allergy Drug Targets; 2015; 14(1):4-12. PubMed ID: 26296210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary.
    Mountifield R
    J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():25-26. PubMed ID: 33817852
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.
    Zundler S; Neurath MF
    Inflamm Bowel Dis; 2017 Apr; 23(4):617-627. PubMed ID: 28296823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin inhibitors go with the gut.
    Holmes D
    Nat Rev Drug Discov; 2013 Jun; 12(6):411-2. PubMed ID: 23722331
    [No Abstract]   [Full Text] [Related]  

  • 9. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
    van Langenberg DR
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
    [No Abstract]   [Full Text] [Related]  

  • 10. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
    Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
    Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intestinal immune response is regulated by gut microbe].
    Tanemoto S; Sujino T; Kanai T
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(6):408-415. PubMed ID: 29367525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut.
    Zundler S; Klingberg A; Schillinger D; Fischer S; Neufert C; Atreya I; Gunzer M; Neurath MF
    Gastroenterology; 2017 Oct; 153(4):898-900. PubMed ID: 28870528
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
    Babickova J; Gardlik R
    World J Gastroenterol; 2015 Oct; 21(40):11321-30. PubMed ID: 26525290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translating nutritional immunology into drug development for inflammatory bowel disease.
    Leber A; Hontecillas R; Tubau-Juni N; Bassaganya-Riera J
    Curr Opin Gastroenterol; 2016 Nov; 32(6):443-449. PubMed ID: 27673381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of integrin antagonists in the treatment of inflammatory bowel disease.
    Beniwal-Patel P; Saha S
    Expert Opin Biol Ther; 2014 Dec; 14(12):1815-23. PubMed ID: 25288228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Existing knowledge of the human gut microbiota.
    Macfarlane G
    J Pediatr Gastroenterol Nutr; 2008 Apr; 46 Suppl 1():E10. PubMed ID: 18354313
    [No Abstract]   [Full Text] [Related]  

  • 17. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal Microbiota in Inflammatory Bowel Disease and Carcinogenesis: Implication for Therapeutics.
    Bruner SD; Jobin C
    Clin Pharmacol Ther; 2016 Jun; 99(6):585-7. PubMed ID: 26850686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gut biofilm forming bacteria in inflammatory bowel disease.
    Srivastava A; Gupta J; Kumar S; Kumar A
    Microb Pathog; 2017 Nov; 112():5-14. PubMed ID: 28942174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.